Extended Data Fig. 4. Biallelic parallel mutation during metastatic prostate cancer evolution.

Heatmap showing allele frequencies of variants found to be biallelic in at least one sample of eight prostate cancers with sequencing of matched primary and metastases (A10–A34, different sites indicated as in Gundem et al.¹²). Early clonal biallelic mutations are detected in all samples of a patient (for example, A10 chr19:29,339,579), while late clonal and subclonal ones show no evidence of being biallelic in some samples (beta-binomial p-value > 0.05 and no discordant phasing to a heterozygous germline SNP) or are detected in only a subset of samples (for example, A22 chr14:61,497,015 and A10 chr2:117,463,664, respectively).